
Dapagliflozin resulted in significant and sustained reductions in first and recurrent HF hospitalizations among patients with HF across the spectrum of ejection fraction according to the DELIVER and DAPA‐HF trials. Of the 1209 HF hospitalizations reported in DELIVER, 71% (854) were uncomplicated, and 29% (355) were complicated. Of the 799 HF hospitalizations reported in DAPA‐HF, 57% (453) were uncomplicated, and 43% (346) were complicated. A substantial proportion of hospitalizations (~30%–40%) among patients with HF, irrespective of ejection fraction, required treatment intensification beyond standard intravenous diuretics. Such patients experienced significantly higher in‐hospital mortality. Treatment with dapagliflozin consistently reduced HF hospitalizations regardless of the severity of the inpatient treatment course or LOS.
Like
Save
Share